Abstract. Cisplatin-based chemotherapy is the standard therapy used for the treatment of several types of cancer. However, its efficacy is largely limited by the acquired drug resistance. To date, little is known about the RNA expression changes in cisplatin-resistant cancers. Identification of the RNAs related to cisplatin resistance may provide specific insight into cancer therapy. In the present study, expression profiling of 7 cancer cell lines was performed using oligonucleotide microarray analysis data obtained from the GEO database. Bioinformatic analyses such as the Gene Ontology (GO) and KEGG pathway were used to identify genes and pathways specifically associated with cisplatin resistance. A signal transduction network was established to identify the core genes in regulating cancer cell cisplatin resistance. A number of genes were differentially expressed in 7 groups of cancer cell lines. They mainly participated in 85 GO terms and 11 pathways in common. All differential gene interactions in the Signal-Net were analyzed. CTNNB1, PLCG2 and SRC were the most significantly altered. With the use of bioinformatics, large amounts of data in microarrays were retrieved and analyzed by means of thorough experimental planning, scientific statistical analysis and collection of complete data on cancer cell cisplatin resistance. In the present study, a novel differential gene expression pattern was constructed and further study will provide new targets for the diagnosis and mechanisms of cancer cisplatin resistance.
Introduction
Cisplatin is primarily effective through DNA damage and is widely used for the treatment of several types of cancer, such as testicular, lung and ovarian cancer. However, the ability of cancer cells to become resistant to cisplatin remains a significant impediment to successful chemotherapy. Although previous studies have identified numerous mechanisms in cisplatin resistance, it remains a major problem that severely limits the usefulness of this chemotherapeutic agent. Therefore, it is crucial to examine more elaborate mechanisms of cisplatin resistance in order to find new targets to prevent drug resistance. Following the rapid development of molecular biology technology, it is possible to detect the molecular differences between the different cells which may provide us with important insights into drug resistance. Thus, it is critical to understand the relationships between cisplatin resistance and molecular changes, as this may aid in the diagnosis of cisplatin resistance and in the improvement of the therapeutic effects of cisplatin.
A number of studies have provided evidence for the molecular changes between cisplatin resistance and wild-type cell lines, indicating the abnormal expression of several genes including ERCC1 and MRP1. However, limited by the development of techniques, several previous studies on cisplatin resistance had difficulties in assisting with clinical research. Firstly, most studies investigated a single molecule, while which pathways it applied to remains unclear. Secondly, most investigated mechanisms referred to a single cancer cell line, and whether a certain hypothesis may apply to another cancer cell line in cisplatin resistance remains unknown.
The advent of genome-wide technologies, such as gene expression microarray, has made it possible to achieve a comprehensive view of the alteration involved in drug resistance. Although several results have been published on cancer cisplatin resistance and although their primary gene expression profile data have been uploaded to the GEO database, no studies have yet combined and investigated these data. In this study, 7 group of cell lines were investigated using gene microarray analysis to examine the differences in gene expression between the cisplatin resistant and wild-type cell lines including the non-small cell lung cancer (NSCLC) cell lines A549 and H460, the ovarian cancer cell line A2780, the oral squamous cancer cell line KB-3-1 and the testicular cancer cell lines 833K, GCT27 and Susa.
Materials and methods
Cell line selection. Cell line microarray data were obtained from 7 datasets including 2 NSCLC cell lines A549 and H460, 1 ovarian cancer cell line A2780, 1 oral squamous cancer cell line KB-3-1 and 3 testicular germ cell tumor (TGCT) cell lines 833K, GCT27 and Susa. The 7 datasets included 1 pair of cisplatin-resistant and 1 pair of wild-type cancer cell lines. Microarray analyses of NSCLC cell lines A549 and A549/CDDP were performed by us using Arraystar Human LncRNA Microarray V2.0 which contained 30,215 coding transcripts. The other 6 data series were accessible at NCBI GEO database, accession numbers were GSE 21656, GSE 33482, GSE 19397 and GSE 14231. The characteristics of the cancer cell lines are presented in Table I .
Differential gene expression.
As some data series had only 2 replicates for arrays in each group, genes differentially expressed between normal and cisplatin-resistant cancer cell lines were identified using the t-test method. Using t-test and the tumors with wild-type as the control group, the P-value and the fold-change were calculated for each differential expression gene. With a threshold of P-value <0.05 and fold-change ≥1.5, cisplatin resistance-related differential expression genes were selected. Unsupervised hierarchical clustering was performed with cluster using Pearson's correlation distance metric and average linkage followed by visualization in Treeview (1) .
Gene Ontology (GO) analysis. Based on the GO Database (http://www.geneontology.org/), the significance level of GOs of the cisplatin resistance-related differentially expressed genes was analyzed by the two-sided Fisher's exact test and using DAVID (http://david.abcc.ncifcrf.gov/home.jsp) analysis (2) . The differential expression genes were analyzed independently according to up-and downregulation of these genes. We computed P-values for all the differential expression genes in all GO categories, and P-value <0.01 was considered to indicate statistically significant differences.
Pathway analysis. Based on the KEGG (http://www.genome. jp/kegg/) database, the significance level of pathways of the cisplatin resistant-related differentially expressed genes was analyzed by Pathway-Express (3,4). Significant differences from the expected were calculated with a two-sided binomial distribution. The number of genes corresponding to each pathway category among the differentially expressed genes was tallied and compared with the number of genes expected for each pathway category. Significant differences from the expected were calculated with a two-sided binomial distribution. All signaling pathways were analyzed for the significance level, using γ P<0.05 as the threshold.
Signal-Net analysis. Using java that allows users to build and analyze molecular networks, network maps were constructed. For instance, if there is confirmative evidence that 2 genes interact with each other, an interaction edge is assigned between the 2 genes. The considered evidence is the source of the interaction database from KEGG. Networks are stored and presented as graphs, where nodes are mainly genes (including protein, compound) and edges represent relation types between the nodes, such as activation or phosphorylation. The graph nature of networks led us to investigate them with powerful tools implemented in R.
To investigate the global network, we computationally identified the most important nodes. Thus, we turned to the connectivity (also known as degree) defined as the sum of connection strengths with the other network genes:
In gene networks, the connectivity measures how a gene correlates with all other network genes. For a gene in the network, the number of source genes of a gene is called the indegree of the gene and the number of target genes of a gene is its outdegree. The character of genes is described by betweenness centrality measures reflecting the importance of a node in a graph relative to other nodes. For a graph G: (V, E) with n vertices, the relative betweenness centrality C B (V) is defined by:
where σ st is the number of shortest paths from s to t, and σ st (V) is the number of shortest paths from s to t that pass through a vertex v (5-9).
Data analysis. The numerical data are presented as the means ± standard deviation (SD). Differences between means were analyzed using the Student's t-test. All statistical analyses were performed using SPSS11.0 software (SPSS Inc., Chicago, IL, USA). Table II . The list shows that each group of cell lines has a similar ratio of differential and total probes. In general, slightly more genes were upregulated than downregulated compared with the control cell lines. Hierarchical clustering showed systematic variations in the expression of mRNAs between the 2 cell lines (Fig. 1) . The results demonstrated that these differential probes could clearly separate the 2 cell lines in all 7 groups.
GO analysis of differential genes in 7 pairs of cancer cell lines. Significant progress in data mining has provided a wide range of bioinformatics analysis options. For example, the GO, which has been proved to be highly beneficial for the mining of functional and biological significance from very large datasets (10, 11) , can produce a controlled vocabulary used for dynamic maintenance and interoperability between genome databases. GO analysis of differential genes in 7 pairs of cancer cell lines was performed by DAVID analysis. Seven groups of GO items merged together and 85 items that appeared >3 times in the 3 groups were obtained (Table III) .
In the biological part of the process, items regarding the downregulation of cell death appeared most times in the 7 cell line pairs and this corresponds to the drug resistance of the cells with high viability. By contrast, cell adhesion-related items generally presented more biological adhesion, cell adhesion and extracellular structure organization. In the cellular component, membrane-related items such as membrane fraction and cell-cell junction were upregulated compared with wild-type cell lines. In the molecular function subgroup, cytoskeletal protein binding and actin binding items variation emerged most in the group.
Pathway analysis of differential genes in 7 pairs of cancer cell lines. The oncogenetic pathways of cisplatin-resistant cancer cell lines were analyzed according to the functions and interactions of the differential genes. By using PathwayExpress which contains both the up-and downregulated differential genes in its analysis and the threshold of significance defined on the basis of γ P-value ≤0.05, tens of significant pathways were found (Figs. 2-8 ). To investigate the frequency in these 7 pairs of cell lines, repeating pathways that appeared in more than half (4 times) were collected and are listed in Table IV . In this table, 11 pathways are listed and phosphatidylinositol signaling system, cell adhesion molecules (CAMs), and leukocyte transendothelial migration appeared in all 7 groups. Furthermore, in the cancer pathway, TGF-β signaling pathway and focal junction have also been reported associated with cisplatin resistance. Therefore, pathway analysis showed us an equally important role and function as GO analysis. Table II . Signal transduction networks composed of 7 pairs of cancer cell lines. According to the literature and experimental records in the databases, 403 genes appearing in previous 11 pathways were collected and a diagram of the gene interaction network was drawn up based on these genes (Fig. 9 ). The total number of genes in the network was 337, and the specific relationships between them are listed in Table V . In the network, cycle nodes represent genes and edges between 2 nodes represent interactions between genes, which were quantified by degree. Degrees within the network which describe the number of single genes that regulate other genes represent the size of the cycle node. The higher the degree, the more central the gene occurs within the network. The clustering coefficient can be used to estimate the complexity of interactions among genes that neighbor the core gene with the exception of core gene participation. The lower the clustering coefficient, the more independent of the core gene are the interactions among genes in the neighborhood of the core gene. Catenin (cadherin-associated protein), β1, 88 kDa (CTNNB1), phospholipase C, γ2 (phosphatidylinositolspecific) (PLCG2) and SRC were the 3 main central genes by degree, while integrin, β8 (ITGB8), PLCB1 and CNTNAP2 were the 3 main genes with the highest frequency of 4.
Discussion
Following the discovery of molecular target drugs, considerable developments have been achieved in treating malignant tumor. However, platinum based chemotherapy remains the main approach in several types of cancer. Resistance acquisition to cisplatin is one of the main problems of the treatment of all tumor types. In recent years, numerous studies have focused on cisplatin resistance and several mechanisms have been proposed. Stewart reviewed the mechanisms of resistance to cisplatin in 2007 by summarizing the 'classical' resistance mechanisms such as drug efflux and DNA repair, and presented some possible genes such as COX-2, epidermal growth factor (EGF) family that may relate to cisplatin resistance (12). Galluzzi et al (13) reviewed the molecular mechanisms of cisplatin resistance again. They classified the mechanisms into 4 alterations and proposed some genes that had been used in clinical chemotherapy prediction. In addition, although several other mechanisms such as microRNA and methylation on cisplatin resistance have previously been identified (14) (15) (16) (17) , their functions in mRNAs remain to be elucidated. Protein is the direct function target of cell behavior, and mRNA is a direct participant in coding protein.
Although the roles of several genes in cisplatin resistance have been reported, there is still a lack of information regarding the general molecular mechanisms in different cancer cells. In this study, a gene expression signature for a subset of cancer Histogram of signal pathways that were significantly different in KB-3-1/CDDP and KB-3-1. x-axis, negative logarithm of the P-value (-LgP); y-axis, the name of the pathway. The larger the -LgP, the smaller the P-value.
cell lines with resistance was established. The 7 cancer cell lines, which were from 4 types of malignant cancer including lung, ovary, testicular and oral cancer, were analyzed jointly. Thereby, our approach emphasizes the involvement of selected genes in general mechanisms of cisplatin resistance acquisition and avoids processes due to individual characteristics of a particular cell line. It is important to note that this is one of few studies on drug resistance that include more than 1 resistant cell line (18).
The present study followed up on microarray-based 7 pairs of cancer cell lines containing 4 types of cancer including NSCLC, ovarian, oral squamous and testicular cancer. All 7 pairs had a wild-type cell line and its cisplatin resistant variation cell line. To clarify molecular changes that may affect cisplatin resistance, we divided the cell lines into 2 groups to obtain cisplatin resistant-related differential expression genes. Expression of the upregulated gene number was in general slightly higher in the cisplatin-resistant group than in the wild-type group. Gene chips have become a useful tool for studying the development and progression of tumors owing to its high throughput, but it remains difficult to predict cancer cell drug resistance, mainly due to marked variation in the range of cisplatin resistance and the significant challenge in interpreting numerous complex data produced by the microarray (19) and determining the main genes responsible. The present study used the bioinformatics method to analyze functions and pathways of the differential expression genes, further clarifying their biological significance, and finally defining the key genes that affected the cisplatin resistance of 4 types of cancer.
For the microarray analyses, 7 cancer cell groups were analyzed on different types of gene chips and their intersection revealed no differentially expressed genes. We used another strategy to investigate their generality by studying their differential gene function at first and then by analysis of their mechanism based on function joint. We first obtained the differential gene function cluster by performing the GO-analysis and pathway analysis which were widely used in high throughput gene data analysis and then we merged these functional analysis results. Since the items in the GO database were numerous and repeated, we set the loose criteria as repetition more than 3 appearances in the 7 lists of GO analysis results. As we integrally considered the factors such as differential expressed genes including both up-and downregulated genes and their fold-changes when performing pathway analysis, we set the strict criteria as repetition frequency to more than half of the 7 lists.
In the latest reviews on molecular mechanisms of cisplatin resistance, the mechanisms were classified into 4 alterations Figure 6 . Histogram of signal pathways that were significantly different in 833K/CDDP and 833K. x-axis, negative logarithm of the P-value (-LgP); y-axis, the name of the pathway. The larger the -LgP, the smaller the P-value. Figure 8 . Histogram of signal pathways that were significantly different in Susa/CDDP and Susa. x-axis, negative logarithm of the P-value (-LgP); y-axis, the name of the pathway. The larger the -LgP, the smaller the P-value. Figure 7 . Histogram of signal pathways that were significantly different in GCT27/CDDP and GCT27. x-axis, negative logarithm of the P-value (-LgP); y-axis, the name of the pathway. The larger the -LgP, the smaller the P-value. including the binding of cisplatin to DNA, direct relation to DNA-cisplatin adducts, the lethal signaling pathway and molecular circuitries that do not present obvious links with cisplatin-elicited signals (13) . The GO is widely recognized as the leading tool for the organization and functional annotation of molecular aspect (20) . GO analysis was used to interpret each GO of differential expressed gene and analyzed it statistically. By using the criteria of P<0.05, significant GOs and genes involved in them were obtained. GO terms regarding programmed cell death in the biological process section plays the most important role in cisplatin resistance, this is easily understood as several genes have been reported to affect cisplatin resistance by participating in lethal signaling pathways elicited by cisplatin-mediated DNA damage (21) (22) (23) . Cell adhesion is another group of items that markedly differently expressed in the merged lists. Dexamethasone has been reported to enhance cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells (24) .
In the cellular component part, membrane-related items such as membrane fraction and cell-cell junction altered significantly indicates molecules affect cisplatin resistance through cell membrane to a large extent. RhoA, ion pumps and membrane lipid have been reported to impact the cell properties of drug resistance (25) (26) (27) . Several protein binding character changes in the molecular function portion also reveal it may be a result of alteration of binding cisplatin to DNA. Based on this, we hypothesized that the other items listed also have a function, which remains unclear, on cisplatin resistance. GO analysis is a classical method to annotate gene function but remains inexact in some fields. Pathway analysis can show the distinct biological process and can find significant pathways that differential expression genes participate in, based on which we can have a comprehensive understanding of the interactions of genes, functions that they participate in and relations between upstream and downstream, and obtain genes involved in these significant pathways. Appearance of pathways on phosphatidylinositol signaling system, cell adhesion molecules and pathways in cancer confirm their concordance with GO terms and their critical role in cisplatin resistance. Numerous studies had proved that the PI3K/Akt signaling pathway, which belongs to the phosphatidylinositol signaling pathway, is involved in different cancer cell cisplatin resistance (28) (29) (30) . The role of cell adhesion molecules has been discussed in the GO analysis part. Adherens junction protein γ-catenin was found downregulated and altered localization in cisplatin-resistant adenocarcinoma cells (31) . Numerous signaling pathways such as MAPK, vascular endothelial growth factor (VEGF) and p53 involved in pathways in cancer have been reported in cisplatin resistance (32-34). Therefore, we have reason to believe the other seemingly irrelevant pathways also have a function in cisplatin resistance and this requires further investigation. Also, pathway analysis showed equally important roles and functions as GO analysis.
Investigating genes involved in significant pathways to form signal transduction network, 337 genes were found in common that may affect the cancer cell cisplatin resistance. Among them, CTNNB1, PLCG2 and SRC performed as the center of the network with the highest degree and ITGB8, PLCB1 and CNTNAP2 were the 3 main genes with the highest frequency. CTNNB1 encodes the core factor of Wnt signaling pathway β-catenin. An increasing number of reports have been published regarding β-catenin even Wnt/β-catenin signaling differently expressed in cisplatin-treated cancer cells (35) (36) (37) . PLCG2 encodes phospholipase C which is thought to mediate Ca 2+ signaling to alter cisplatin sensitivity in head and neck squamous cell carcinoma (38) . SRC is a classic mRNA that activates the tyrosine phosphorylation of several cell pathways and was found to induce cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells early in 1999 (39) . Meanwhile, we focused on the genes with the highest repetition frequency in the network. There is still no report on the role of ITGB8 in cisplatin resistance but it has been found to suppress tumor growth regulated by miRNA-93 (40) . PLCB1 and CNTNAP2 mainly focus their function on neurological disease (41) (42) (43) (44) . Based on these records, the network guides our attention more on genes with higher degree but not on genes that appear more in different cell lines. Furthermore, several genes with high degree in the network have also been found to have a role in cisplatin resistance such as EGFR and PRKC. This network provides us with a number of potential genes that may relate to cancer cisplatin resistance and guide us for further investigation.
The above results suggest that differences in gene expression exist between 7 pairs of cancer cell lines. These genes encode proteins involved in different GOs and signal pathways, the disruption of which can cause cisplatin resistance. Several genes and pathways provide potential candidates for distinguishing between types of cancer and whether they contain characteristics of cisplatin resistance in the future. This distinction will aid in the diagnosis and prevention of cancer cell cisplatin resistance, based on their different characteristics. 
